Brand Name
|
Description |
---|---|
Abstral™ (sublingual fentanyl) |
Abstral™ is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain |
Caphosol® (Dibasic Sodium Phosphate Monobasic Sodium Phosphate Calcium Chloride ) |
Caphosol® is indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol® is also indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain. |
PecFent® (fentanyl citrate nasal spray, solution) |
PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. |
Sancuso® (granisetron transdermal patch) |
SANCUSO transdermal patch is indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult |
Brand Name
|
Description |
---|---|
Halaven® (eribulin mesilate) |
Halaven® is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. It is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease |
Lenvima® (lenvatinib) |
Lenvima® is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. It is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy |
Brand Name
|
Description |
---|---|
Brukinsa® (zanubrutinib) |
Brukinsa® is indicated for the treatment of adults with mantle cell lymphoma who have received at least one prior treatment for their cancer. |
Diseases
|
Description |
---|---|
Multicentric Castleman's Disease |
Multicentric Castleman Disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes. The signs and symptoms of MCD are often nonspecific, and are mild in some people but serious in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. For more information on available treatment options, please contact us on [email protected] |
Neuroblastoma |
Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the 1st month of life. The tumor most often develops in the adrenal gland, but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body. In most cases, it has spread by the time it is diagnosed. A Neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. For more information on available treatment options, please contact us on [email protected] |